Seribantumab is a monoclonal antibody commercialized by Elevation Oncology, with a leading Phase II program in Gallbladder Cancer. According to Globaldata, it is involved in 13 clinical trials, of which 9 were completed, 1 is ongoing, and 3 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Seribantumab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Seribantumab is expected to reach an annual total of $24 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Seribantumab Overview

Seribantumab (MM-121, SAR-256212) is under development for the treatment of NRG1 gene fusion positive solid tumors including pancreatic cancer, lung cancer, head and neck cancer, breast cancer, kidney cancer, colorectal cancer, bladder cancer, ovarian cancer, sarcoma, gallbladder cancer, bile duct cancer, esophageal cancer, uterine cancer and prostate cancer. The drug candidate is administered through intravenous route. MM-121 is a fully human IgG2 antibody that targets human epidermal growth factor receptor 3 (ErbB3 or EGFR3).

It was also under development for HER2 negative metastatic or triple negative breast cancer, platinum-resistant/refractory ovarian cancer, fallopian tube cancer, peritoneal cancer, endometrial cancer, squamous cell head and neck cancer (second line), non-small cell lung cancer, and epithelial ovarian cancer.

Elevation Oncology Overview

Elevation Oncology is a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients. Elevation Oncology is headquartered in New York City, New York, the US.

The operating loss of the company was US$32.1 million in FY2021, compared to an operating loss of US$17.3 million in FY2020. The net loss of the company was US$32 million in FY2021, compared to a net loss of US$17.3 million in FY2020.

For a complete picture of Seribantumab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.